In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the right Contract Development and Manufacturing Organization (CDMO) for drug product…
The post Key Factors for Choosing…
Loss of exclusivity (LOE) doesn’t have to spell doom for branded drug revenue streams. In the face of impending patent expirations, pharmaceutical companies can adopt key approaches to preserve meaningful…
The post Strategies to Maximize Product Value …
A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs. Over the past three decades, biotherapeutics have revolutionized healthcare by providing effective treatments for complex diseases…
The post Unsuccessf…
Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review Read Post »
DrugPatentWatch now offers single drug reports for purchase on Amazon. These reports provide valuable insights and information about specific drugs. This convenient availability on Amazon allows users to easily access…
The post Drug Patent Reports now …
A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in the pharmaceutical industry for drug discovery and development. Results The…
The post Artificial Intelligence and Machi…
Artificial Intelligence and Machine Learning in Drug Discovery and Development Read Post »
A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs that are marketed without their original branding. The article sheds…
The post Prevalence and timing of au…
Prevalence and timing of authorized generics in the US market Read Post »
A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based…
The post Insights into Shifting Dynamics: O…
Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends Read Post »
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status of reverse payment cases against pharmaceutical companies. Reverse payment cases…
The post The Evolution of Reverse Paym…
In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of generic competition. One such strategy is the use of “authorized…
The post Understanding the Impact of Authorized G…
A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020. The study…
The post Review of 505(b)(2) Drug Products Approved by USFDA from 2…